Biotech Holdings retains corporate development company
Robert Rieveley, President of Biotech Holdings announced that the company has recently retained Erythana Ventures Corp. to provide assistance with corporate development.
"At the Company's current development point, with our diabetes drug now on the market in Mexico, we have retained Erythana to assist with the realization of our potential, both in terms of corporate activity and market value," Mr. Rieveley said.
"Erythana has a 21-year operating history, working with clients from offices in Vancouver and Calgary. Erythana has been retained by more than 350 corporate, institutional and government clients, in more than a dozen countries. We believe that Erythana and its principal, Si Brown, can offer Biotech valuable assistance with our corporate growth," Mr. Rieveley said.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.